###begin article-title 0
Increased osteoclastic activity in acute Charcot's osteoarthopathy: the role of receptor activator of nuclear factor-kappaB ligand
###end article-title 0
###begin title 1
Aims/hypothesis
###end title 1
###begin p 2
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Our aims were to compare osteoclastic activity between patients with acute Charcot's osteoarthropathy and diabetic and healthy controls, and to determine the effect of the receptor activator of nuclear factor-kappaB ligand (RANKL) and its decoy receptor osteoprotegerin (OPG).
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 63 71 <span type="species:ncbi:9606">patients</span>
###xml 122 134 <span type="species:ncbi:9606">participants</span>
Peripheral blood monocytes isolated from nine diabetic Charcot patients, eight diabetic control and eight healthy control participants were cultured in the presence of macrophage-colony stimulating factor (M-CSF) alone, M-CSF and RANKL, and also M-CSF and RANKL with excess concentrations of OPG. Osteoclast formation was assessed by expression of tartrate-resistant acid phosphatase on glass coverslips and resorption on dentine slices.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 158 159 158 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 298 299 298 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 461 462 457 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 530 531 522 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 628 629 616 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 795 796 779 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 911 912 891 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 997 998 973 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
###xml 144 156 <span type="species:ncbi:9606">participants</span>
###xml 284 296 <span type="species:ncbi:9606">participants</span>
###xml 542 550 <span type="species:ncbi:9606">patients</span>
###xml 580 592 <span type="species:ncbi:9606">participants</span>
###xml 754 762 <span type="species:ncbi:9606">patients</span>
###xml 867 875 <span type="species:ncbi:9606">patients</span>
###xml 945 957 <span type="species:ncbi:9606">participants</span>
In cultures with M-CSF, there was a significant increase in osteoclast formation in Charcot patients compared with healthy and diabetic control participants (p = 0.008). A significant increase in bone resorption was also seen in the former, compared with healthy and diabetic control participants (p < 0.0001). The addition of RANKL to the cultures with M-CSF led to marked increase in osteoclastic resorption in Charcot (from 0.264 +/- 0.06% to 41.6 +/- 8.1%, p < 0.0001) and diabetic control (0.000 +/- 0.00% to 14.2 +/- 16.5%, p < 0.0001) patients, and also in healthy control participants (0.004 +/- 0.01% to 10.5 +/- 1.9%, p < 0.0001). Although the addition of OPG to cultures with M-CSF and RANKL led to a marked reduction of resorption in Charcot patients (41.6 +/- 8.1% to 5.9 +/- 2.4%, p = 0.001), this suppression was not as complete as in diabetic control patients (14.2 +/- 16.5% to 0.45 +/- 0.31%, p = 0.001) and in healthy control participants (from 10.5 +/- 1.9% to 0.00 +/- 0.00%, p < 0.0001).
###end p 6
###begin title 7
Conclusions/interpretation
###end title 7
###begin p 8
These results indicate that RANKL-mediated osteoclastic resorption occurs in acute Charcot's osteoarthropathy. However, the incomplete inhibition of RANKL after addition of OPG also suggests the existence of a RANKL-independent pathway.
###end p 8
###begin title 9
Keywords
###end title 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 89 90 89 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 284 285 284 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 649 650 649 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 1351 1352 1351 1352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
Although Charcot's osteoarthropathy is characterised by increased local bone resorption [1], the exact cellular mechanisms contributing to the pathogenesis of this condition remain unresolved. Osteoclasts have been shown to be the principal cell type responsible for bone resorption [2]. These cells originate from the haemopoietic lineage and are known to undergo various stages of proliferation, fusion and differentiation before they are fully functionally active, mature osteoclasts. Recently, receptor activator of nuclear factor-kappaB (RANK) ligand (RANKL) has been identified as an essential mediator of osteoclast formation and activation [3]. RANKL is expressed on a variety of cell types such as bone forming osteoblasts, T lymphocytes, dendritic cells, endothelial cells and fibroblasts. RANKL mediates the process of osteoclastogenesis by binding to its RANK, which is expressed on mononuclear osteoclast precursors. The effects of RANKL-RANK interaction are physiologically counterbalanced by osteoprotegerin (OPG), which acts as a soluble receptor decoy for RANKL and blocks the interaction of RANKL with RANK. The ratio of RANKL to OPG has been suggested to regulate the extent of osteoclast formation and resorption. Therefore, any alteration in the RANKL/OPG ratio could be critical in the pathogenesis of osteolytic bone disorders [4].
###end p 11
###begin p 12
###xml 152 153 152 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 266 267 266 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 334 335 334 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 207 212 <span type="species:ncbi:9606">human</span>
###xml 578 586 <span type="species:ncbi:9606">patients</span>
Recently, Jeffcoate hypothesised that the RANK/RANKL/OPG pathway may play an important role in the osteolysis seen in acute Charcot's osteoarthropathy [5]. Using an in vitro technique to generate functional human osteoclasts from peripheral blood monocytes (PBMCs) [6] in the presence of macrophage-colony stimulating factor (M-CSF) [7] and soluble RANKL, it is possible to determine the cellular mechanisms involved in the process of osteoclast formation and resorption in physiological and pathological conditions. To our knowledge, this technique has not yet been studied in patients with Charcot's osteoarthropathy.
###end p 12
###begin p 13
###xml 56 61 <span type="species:ncbi:9606">human</span>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
###xml 182 194 <span type="species:ncbi:9606">participants</span>
The aims of this study were: (1) to generate functional human osteoclasts in vitro from diabetic patients with acute Charcot's osteoarthropathy and from healthy and diabetic control participants; (2) to compare the extent of osteoclast formation and resorption; and (3) to determine the role of the RANK/RANKL/OPG pathway in osteoclastic activity in Charcot's osteoarthropathy.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 15
###begin p 16
###xml 687 688 681 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 807 808 797 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 946 947 932 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1093 1094 1075 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 37 45 <span type="species:ncbi:9606">patients</span>
###xml 106 109 <span type="species:ncbi:9606">men</span>
###xml 116 121 <span type="species:ncbi:9606">women</span>
###xml 174 182 <span type="species:ncbi:9606">patients</span>
###xml 244 247 <span type="species:ncbi:9606">men</span>
###xml 255 260 <span type="species:ncbi:9606">women</span>
###xml 314 326 <span type="species:ncbi:9606">participants</span>
###xml 333 336 <span type="species:ncbi:9606">men</span>
###xml 344 349 <span type="species:ncbi:9606">women</span>
###xml 352 360 <span type="species:ncbi:9606">Patients</span>
###xml 471 479 <span type="species:ncbi:9606">patients</span>
###xml 517 529 <span type="species:ncbi:9606">participants</span>
###xml 564 572 <span type="species:ncbi:9606">patients</span>
###xml 626 634 <span type="species:ncbi:9606">patients</span>
###xml 757 769 <span type="species:ncbi:9606">participants</span>
###xml 911 919 <span type="species:ncbi:9606">patients</span>
We studied nine consecutive diabetic patients with recent onset of acute Charcot's osteoarthropathy (five men, four women; five type 1, four type 2 diabetes), eight diabetic patients with no previous history of Charcot's osteoarthropathy (five men, three women; four type 1, four type 2) and eight healthy control participants (five men, three women). Patients with acute Charcot's osteoarthropathy were matched for age and duration of diabetes with the diabetic control patients and for age with the healthy control participants. The mean age was similar between patients with Charcot's osteoarthropathy and diabetic control patients (53 +/- 2.8 versus 59 +/- 2.9 years [mean +/- SEM], p = 0.167) as was the mean age between the former and healthy control participants (53 +/- 2.8 versus 47 +/- 2.7 years, p = 0.114). The mean duration of diabetes was similar in both groups with diabetes (31 +/- 5.1 [Charcot patients] versus 27 +/- 4.6 years, p = 0.606). Diabetes control as indicated by glycated Hb was also similar in the two diabetes groups (7.7 +/- 0.6 [Charcot's] versus 7.8 +/- 0.4%, p = 0.743).
###end p 16
###begin p 17
###xml 312 313 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 320 328 <span type="species:ncbi:9606">patients</span>
Diagnosis of Charcot's osteoarthropathy was made on the presentation of a hot swollen foot, with skin foot temperature 2degreesC greater than the corresponding site on the contralateral foot and with typical radiological changes of subluxation, dislocation or fragmentation of bone on standard foot radiographs [8]. All patients had intact feet and no evidence of foot infection or ulceration.
###end p 17
###begin p 18
###xml 114 126 <span type="species:ncbi:9606">participants</span>
Ethical permission for this study was obtained from the King's College Hospital Research Ethics Committee and all participants gave written informed consent.
###end p 18
###begin title 19
Isolation and culture of monocytes
###end title 19
###begin p 20
###xml 74 75 74 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 220 221 216 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 301 302 297 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
Peripheral blood mononuclear cells were isolated as previously described [6]. Briefly, blood was diluted 1:1 in alpha-minimum essential medium (MEM; Invitrogen, Paisley, UK), layered over Histopaque and centrifuged (693 g) for 20 min. The interface layer was resuspended in MEM, then centrifuged (600 g) for a further 10 min. The resultant cells were resuspended in MEM with 10% heat-inactivated FCS and counted in a haemocytometer following lysis of erythrocytes by a 5% (vol./vol.) acetic acid solution.
###end p 20
###begin p 21
###xml 138 139 138 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 523 528 <span type="species:ncbi:9606">human</span>
###xml 614 619 <span type="species:ncbi:9606">human</span>
###xml 833 838 <span type="species:ncbi:9606">human</span>
To assess the extent of osteoclast formation and resorption, PBMCs were cultured on glass coverslips and dentine slices. Initially, 5 x 105 PBMCs were added to 6-mm diameter glass coverslips and 4-mm diameter dentine slices in MEM containing 100 UI/ml penicillin, 100 mug/ml streptomycin and 10% FCS (Gibco, Paisley, UK). After 2 h incubation, coverslips and dentine slices were vigorously rinsed in medium to remove non-adherent cells. The cultures were maintained in MEM/FCS under three different culture conditions: (1) human M-CSF (R&D Systems Europe, Abingdon, UK) alone at 25 ng/ml; (2) M-CSF plus 100 ng/ml human soluble RANKL (sRANKL; Peprotech, London, UK) (a concentration known to facilitate differentiation of osteoclast precursors to active bone-resorbing osteoclasts in vitro); and (3) M-CSF plus sRANKL plus 250 ng/ml human OPG (R&D Systems Europe).
###end p 21
###begin p 22
###xml 66 67 60 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Coverslips and dentine slices were cultured at 37degreesC in 5% CO2 for 14 and 21 days respectively.
###end p 22
###begin title 23
Osteoclast formation
###end title 23
###begin p 24
After 14 days, the coverslips were examined histochemically for the expression of tartrate-resistant acid phosphatase (TRAcP), an osteoclast marker. Coverslips with newly formed osteoclasts were collected and rinsed in PBS buffer, fixed with formalin (10% [vol./vol.] in PBS buffer) for 10 min and rinsed in distilled water. TRAcP was histochemically revealed by a simultaneous coupling reaction using Naphtol AS-BI-phosphate as substrate and Fast violet B as the diazonium salt. The coverslips were incubated for 90 min at 37degreesC in a dark room, rinsed three times in distilled water and the residual activity was inhibited by 4% NaF (wt/wt) for 30 min. Coverslips were then rinsed in distilled water, counterstained with DAPI for 20 min and allowed to dry before mounting, using an aqueous medium. TRAcP-positive cells with more than three nuclei were identified as osteoclasts. The number of newly generated osteoclasts was assessed using a light microscope examination.
###end p 24
###begin title 25
Osteoclast resorption
###end title 25
###begin p 26
###xml 83 84 83 84 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
After 21 days, the dentine slices were removed from the culture wells, placed in NH4OH (1 mol/l) for 30 min and sonicated for 5 min to remove any adherent cells. They were then rinsed in distilled water and stained with 0.5% (vol./vol.) toluidine blue prior to examination by light microscopy. The surface of each dentine slice was examined for evidence of lacunar resorption and the extent of eroded surface on each dentine slice was determined using image analysis and expressed as the percentage of surface area resorbed.
###end p 26
###begin title 27
Statistical analyses
###end title 27
###begin p 28
###xml 354 355 352 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 482 483 480 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 533 534 531 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 103 111 <span type="species:ncbi:9606">patients</span>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
###xml 275 283 <span type="species:ncbi:9606">patients</span>
###xml 370 377 <span type="species:ncbi:9606">patient</span>
Data were expressed as a mean +/- SEM. Initially the difference within the three study groups (Charcot patients, healthy and diabetic controls) was assessed with the non-parametric Kruskall-Wallis test. Then the differences between Charcot and diabetic patients, and Charcot patients and healthy controls were assessed by the non-parametric Mann-Whitney U test. In each patient group, the differences between the various culture conditions were also assessed using the Mann-Whitney U test. Differences were considered significant at p < 0.05.
###end p 28
###begin title 29
Results
###end title 29
###begin title 30
Osteoclast cultures in the presence of M-CSF
###end title 30
###begin p 31
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Osteoclast formation</bold>
###xml 301 302 295 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 473 474 467 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 512 513 506 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 159 167 <span type="species:ncbi:9606">patients</span>
###xml 273 285 <span type="species:ncbi:9606">participants</span>
Osteoclast formation The mean number of newly formed TRAcP-positive multinucleated osteoclasts in the presence of M-CSF alone was significantly greater in the patients with acute Charcot's osteoarthropathy (48.6 +/- 18.2) than in diabetic (6.8 +/- 2.7) and healthy control participants (5.0 +/- 0.7) (p = 0.008). The number of TRAcP-positive multinucleated osteoclasts formed in acute Charcot's osteoarthropathy was 7.2 and 9.7 times greater than those formed in diabetic (p = 0.010) and healthy control groups (p = 0.003), respectively.
###end p 31
###begin p 32
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Osteoclast resorption</bold>
###xml 367 368 361 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 481 482 475 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 520 521 514 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 216 224 <span type="species:ncbi:9606">patients</span>
###xml 450 458 <span type="species:ncbi:9606">patients</span>
Osteoclast resorption The newly formed osteoclasts exhibited increased functional activity as demonstrated by the extent of resorption on dentine slices, with percentage area resorption significantly elevated in the patients with acute Charcot's osteoarthropathy (0.264 +/- 0.06%) compared with diabetic (0.000 +/- 0.00%) and healthy control groups (0.004 +/- 0.01) (p < 0.0001). The percentage of resorption was significantly greater in the Charcot patients than in the diabetic (p = 0.001) and healthy control groups (p = 0.001).
###end p 32
###begin title 33
Osteoclast cultures in the presence of M-CSF and sRANKL
###end title 33
###begin p 34
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Osteoclast formation</bold>
###xml 378 379 372 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 394 395 388 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 614 615 608 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 770 771 764 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 995 996 985 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1073 1074 1059 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1266 1267 1248 1249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1282 1283 1264 1265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1287 1293 1269 1275 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 1362 1363 1344 1345 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1365 1366 1347 1348 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1368 1369 1350 1351 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 1402 1403 1384 1385 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1405 1406 1387 1388 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 1408 1409 1390 1391 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 1600 1601 1582 1583 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1603 1604 1585 1586 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1630 1631 1612 1613 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1633 1634 1615 1616 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 1657 1658 1639 1640 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 1660 1661 1642 1643 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 1293 1695 1275 1676 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35">Multinucleated TRAcP-positive cells were formed on glass coverslips (<bold>a</bold>, <bold>c</bold>, <bold>e</bold>) capable of lacunar resorption (<bold>b</bold>, <bold>d</bold>, <bold>f</bold>) after 14 and 21&#160;days incubation, respectively, in the presence of 25&#160;ng/ml human M-CSF and 100&#160;ng/ml sRANKL. Newly formed osteoclasts were numerous and highly active in Charcot&#8217;s patients (<bold>a</bold>, <bold>b</bold>) compared with diabetic (<bold>c</bold>, <bold>d</bold>) and healthy control (<bold>e</bold>, <bold>f</bold>) participants. Scale bars, 10&#160;&#956;m</p>
###xml 1293 1695 1275 1676 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35">Multinucleated TRAcP-positive cells were formed on glass coverslips (<bold>a</bold>, <bold>c</bold>, <bold>e</bold>) capable of lacunar resorption (<bold>b</bold>, <bold>d</bold>, <bold>f</bold>) after 14 and 21&#160;days incubation, respectively, in the presence of 25&#160;ng/ml human M-CSF and 100&#160;ng/ml sRANKL. Newly formed osteoclasts were numerous and highly active in Charcot&#8217;s patients (<bold>a</bold>, <bold>b</bold>) compared with diabetic (<bold>c</bold>, <bold>d</bold>) and healthy control (<bold>e</bold>, <bold>f</bold>) participants. Scale bars, 10&#160;&#956;m</p></caption>
###xml 1695 1695 1676 1676 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="125_2008_992_Fig1_HTML" id="MO1"/>
###xml 1287 1695 1269 1676 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="35">Multinucleated TRAcP-positive cells were formed on glass coverslips (<bold>a</bold>, <bold>c</bold>, <bold>e</bold>) capable of lacunar resorption (<bold>b</bold>, <bold>d</bold>, <bold>f</bold>) after 14 and 21&#160;days incubation, respectively, in the presence of 25&#160;ng/ml human M-CSF and 100&#160;ng/ml sRANKL. Newly formed osteoclasts were numerous and highly active in Charcot&#8217;s patients (<bold>a</bold>, <bold>b</bold>) compared with diabetic (<bold>c</bold>, <bold>d</bold>) and healthy control (<bold>e</bold>, <bold>f</bold>) participants. Scale bars, 10&#160;&#956;m</p></caption><graphic position="anchor" xlink:href="125_2008_992_Fig1_HTML" id="MO1"/></fig>
###xml 1695 1701 1676 1682 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 1701 1702 1682 1683 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1747 1748 1728 1729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1952 1953 1933 1934 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2140 2141 2121 2122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 2178 2179 2159 2160 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 2190 2191 2171 2172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2218 2219 2199 2200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2245 2246 2226 2227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2256 2257 2237 2238 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2268 2269 2249 2250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2297 2298 2278 2279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2325 2326 2306 2307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1701 2335 1682 2316 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36"><bold>a</bold> Quantitative comparison between the number (<italic>n</italic>) of TRAcP-positive cells formed in cultures with M-CSF alone (white bars) or with M-CSF and sRANKL (black bars) in patients with Charcot&#8217;s osteoarthropathy and diabetic and healthy control participants. <bold>b</bold> Quantitative comparison between the percentage area resorption in the same cultures and patient groups. Statistical differences between the groups were determined using the Mann&#8211;Whitney <italic>U</italic> test, with significance as follows: <bold>a</bold> Charcot&#8217;s <italic>p</italic>&#8201;=&#8201;0.059, diabetic control <italic>p</italic>&#8201;=&#8201;0.003, healthy control <italic>p</italic>&#8201;=&#8201;0.002; <bold>b</bold> Charcot&#8217;s <italic>p</italic>&#8201;&lt;&#8201;0.0001, diabetic control <italic>p</italic>&#8201;&lt;&#8201;0.0001, healthy control <italic>p</italic>&#8201;&lt;&#8201;0.0001</p>
###xml 1701 2335 1682 2316 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36"><bold>a</bold> Quantitative comparison between the number (<italic>n</italic>) of TRAcP-positive cells formed in cultures with M-CSF alone (white bars) or with M-CSF and sRANKL (black bars) in patients with Charcot&#8217;s osteoarthropathy and diabetic and healthy control participants. <bold>b</bold> Quantitative comparison between the percentage area resorption in the same cultures and patient groups. Statistical differences between the groups were determined using the Mann&#8211;Whitney <italic>U</italic> test, with significance as follows: <bold>a</bold> Charcot&#8217;s <italic>p</italic>&#8201;=&#8201;0.059, diabetic control <italic>p</italic>&#8201;=&#8201;0.003, healthy control <italic>p</italic>&#8201;=&#8201;0.002; <bold>b</bold> Charcot&#8217;s <italic>p</italic>&#8201;&lt;&#8201;0.0001, diabetic control <italic>p</italic>&#8201;&lt;&#8201;0.0001, healthy control <italic>p</italic>&#8201;&lt;&#8201;0.0001</p></caption>
###xml 2335 2335 2316 2316 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="125_2008_992_Fig2_HTML" id="MO2"/>
###xml 1695 2335 1676 2316 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="36"><bold>a</bold> Quantitative comparison between the number (<italic>n</italic>) of TRAcP-positive cells formed in cultures with M-CSF alone (white bars) or with M-CSF and sRANKL (black bars) in patients with Charcot&#8217;s osteoarthropathy and diabetic and healthy control participants. <bold>b</bold> Quantitative comparison between the percentage area resorption in the same cultures and patient groups. Statistical differences between the groups were determined using the Mann&#8211;Whitney <italic>U</italic> test, with significance as follows: <bold>a</bold> Charcot&#8217;s <italic>p</italic>&#8201;=&#8201;0.059, diabetic control <italic>p</italic>&#8201;=&#8201;0.003, healthy control <italic>p</italic>&#8201;=&#8201;0.002; <bold>b</bold> Charcot&#8217;s <italic>p</italic>&#8201;&lt;&#8201;0.0001, diabetic control <italic>p</italic>&#8201;&lt;&#8201;0.0001, healthy control <italic>p</italic>&#8201;&lt;&#8201;0.0001</p></caption><graphic position="anchor" xlink:href="125_2008_992_Fig2_HTML" id="MO2"/></fig>
###xml 145 153 <span type="species:ncbi:9606">patients</span>
###xml 195 203 <span type="species:ncbi:9606">patients</span>
###xml 466 474 <span type="species:ncbi:9606">patients</span>
###xml 559 567 <span type="species:ncbi:9606">patients</span>
###xml 950 958 <span type="species:ncbi:9606">patients</span>
###xml 1025 1037 <span type="species:ncbi:9606">participants</span>
###xml 1486 1491 <span type="species:ncbi:9606">human</span>
###xml 1590 1598 <span type="species:ncbi:9606">patients</span>
###xml 1663 1675 <span type="species:ncbi:9606">participants</span>
###xml 1864 1872 <span type="species:ncbi:9606">patients</span>
###xml 1938 1950 <span type="species:ncbi:9606">participants</span>
###xml 2042 2049 <span type="species:ncbi:9606">patient</span>
Osteoclast formation The addition of sRANKL led to an increase in the number of TRAcP-positive multinucleated osteoclasts in all three groups of patients. The mean number of these osteoclasts in patients with acute Charcot's osteoarthropathy was 96.0 +/- 21.6, which was significantly greater than that in the diabetic (56.5 +/- 11.5) and healthy (29.0 +/- 5.1) control groups (p = 0.010; Fig. 1a,c,e). The number of TRAcP-positive multinucleated osteoclasts in the patients with acute Charcot's osteoarthropathy was 1.7 times higher than in diabetic control patients, but this finding did not reach significance (p = 0.105). However, the number of these osteoclasts in the acute Charcot group was 3.3 times (and significantly) higher than in the healthy control group (p = 0.005). When the number of cells in the cultures with M-CSF alone was compared with that after the addition of sRANKL, there was a significant increase in the diabetic control patients (from 6.8 +/- 2.7 to 56.5 +/- 11.5, p = 0.003) and in the healthy participants (from 5.0 +/- 0.7 to 29.0 +/- 5.1, p = 0.002), while the increase in the number of TRAcP-positive multinucleated osteoclasts in the acute Charcot group failed to reach significance (increase from 48.6 +/- 18.2 to 96.0 +/- 21.6, p = 0.059; Fig. 2a). Fig. 1Multinucleated TRAcP-positive cells were formed on glass coverslips (a, c, e) capable of lacunar resorption (b, d, f) after 14 and 21 days incubation, respectively, in the presence of 25 ng/ml human M-CSF and 100 ng/ml sRANKL. Newly formed osteoclasts were numerous and highly active in Charcot's patients (a, b) compared with diabetic (c, d) and healthy control (e, f) participants. Scale bars, 10 mumFig. 2a Quantitative comparison between the number (n) of TRAcP-positive cells formed in cultures with M-CSF alone (white bars) or with M-CSF and sRANKL (black bars) in patients with Charcot's osteoarthropathy and diabetic and healthy control participants. b Quantitative comparison between the percentage area resorption in the same cultures and patient groups. Statistical differences between the groups were determined using the Mann-Whitney U test, with significance as follows: a Charcot's p = 0.059, diabetic control p = 0.003, healthy control p = 0.002; b Charcot's p < 0.0001, diabetic control p < 0.0001, healthy control p < 0.0001
###end p 34
###begin p 35
###xml 69 70 69 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 72 73 72 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 75 76 75 76 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 109 110 109 110 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 112 113 112 113 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 115 116 115 116 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 307 308 307 308 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 310 311 310 311 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 337 338 337 338 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 340 341 340 341 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 364 365 364 365 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 367 368 367 368 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 193 198 <span type="species:ncbi:9606">human</span>
###xml 297 305 <span type="species:ncbi:9606">patients</span>
###xml 370 382 <span type="species:ncbi:9606">participants</span>
Multinucleated TRAcP-positive cells were formed on glass coverslips (a, c, e) capable of lacunar resorption (b, d, f) after 14 and 21 days incubation, respectively, in the presence of 25 ng/ml human M-CSF and 100 ng/ml sRANKL. Newly formed osteoclasts were numerous and highly active in Charcot's patients (a, b) compared with diabetic (c, d) and healthy control (e, f) participants. Scale bars, 10 mum
###end p 35
###begin p 36
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 46 47 46 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 251 252 251 252 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 439 440 439 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 477 478 477 478 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 489 490 489 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 517 518 517 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 544 545 544 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 555 556 555 556 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 567 568 567 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 596 597 596 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 624 625 624 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 163 171 <span type="species:ncbi:9606">patients</span>
###xml 237 249 <span type="species:ncbi:9606">participants</span>
###xml 341 348 <span type="species:ncbi:9606">patient</span>
a Quantitative comparison between the number (n) of TRAcP-positive cells formed in cultures with M-CSF alone (white bars) or with M-CSF and sRANKL (black bars) in patients with Charcot's osteoarthropathy and diabetic and healthy control participants. b Quantitative comparison between the percentage area resorption in the same cultures and patient groups. Statistical differences between the groups were determined using the Mann-Whitney U test, with significance as follows: a Charcot's p = 0.059, diabetic control p = 0.003, healthy control p = 0.002; b Charcot's p < 0.0001, diabetic control p < 0.0001, healthy control p < 0.0001
###end p 36
###begin p 37
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Osteoclast resorption</bold>
###xml 259 260 253 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 362 363 356 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 425 426 419 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 441 442 435 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 637 638 627 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 701 702 687 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 763 764 745 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 780 781 762 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 297 305 <span type="species:ncbi:9606">patients</span>
###xml 352 360 <span type="species:ncbi:9606">patients</span>
###xml 411 423 <span type="species:ncbi:9606">participants</span>
Osteoclast resorption The percentage area resorption on dentine slices with M-CSF and sRANKL was significantly increased in the acute Charcot group (41.6 +/- 8.1%) compared with that in the diabetic (14.2 +/- 16.5%) and healthy control groups (10.5 +/- 1.9%; p = 0.005). Resorption in the Charcot patients was 2.9 times higher than in diabetic control patients (p = 0.008) and four times higher than in healthy participants (p = 0.005; Fig. 1b,d,f). The addition of sRANKL to the cultures with M-CSF led to the following rises in the percentage area resorption when compared with M-CSF alone: Charcot's 0.264 +/- 0.06% to 41.6 +/- 8.1%, p < 0.0001; diabetic control 0.000 +/- 0.00% to 14.2 +/- 16.5%, p < 0.0001; healthy control 0.004 +/- 0.01% to 10.5 +/- 1.9%, p < 0.0001 (Fig. 2b).
###end p 37
###begin title 38
Osteoclast cultures in the presence of M-CSF, sRANKL and excess concentrations of OPG
###end title 38
###begin p 39
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Osteoclast formation</bold>
###xml 475 476 469 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 645 646 639 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 684 685 678 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 214 222 <span type="species:ncbi:9606">patients</span>
###xml 448 460 <span type="species:ncbi:9606">participants</span>
###xml 614 622 <span type="species:ncbi:9606">patients</span>
Osteoclast formation The addition of excess concentrations of OPG led to a reduction in the number of TRAcP-positive multinucleated osteoclasts in the cultures with M-CSF, sRANKL and OPG in all the three groups of patients. However, after the addition of OPG, the number of TRAcP-positive multinucleated osteoclasts was still significantly increased in the Charcot group (54.4 +/- 17.6), as compared with diabetic (8.8 +/- 5.3) and healthy control participants (4.4 +/- 1.2; p = 0.003). In the cultures with M-CSF, sRANKL and OPG, the number of TRAcP-positive multinucleated osteoclasts was greater in the Charcot patients than in the diabetic (p = 0.005) and healthy control groups (p = 0.001).
###end p 39
###begin p 40
###xml 187 188 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 375 376 367 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 449 450 437 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 465 466 453 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 470 476 458 464 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 476 477 464 465 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 509 510 497 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 760 761 748 749 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 935 936 923 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 973 974 961 962 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 985 986 973 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1013 1014 1001 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1040 1041 1028 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1051 1052 1039 1040 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1063 1064 1051 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1091 1092 1079 1080 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1118 1119 1106 1107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 476 1128 464 1116 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="41"><bold>a</bold> Comparison between the number (<italic>n</italic>) of TRAcP-positive cells formed in cultures with M-CSF and sRANKL (black bars) or with M-CSF, sRANKL and excess concentrations of OPG (250&#160;ng/ml) (grey bars) in patients with Charcot&#8217;s osteoarthropathy and diabetic and healthy control participants. <bold>b</bold> Comparison between the percentage area resorption in the same cultures and patient groups. Statistical differences between the groups were determined using the Mann&#8211;Whitney <italic>U</italic> test, with significance as follows: <bold>a</bold> Charcot&#8217;s <italic>p</italic>&#8201;=&#8201;0.189, diabetic control <italic>p</italic>&#8201;=&#8201;0.005, healthy control <italic>p</italic>&#8201;=&#8201;0.003; <bold>b</bold> Charcot's <italic>p</italic>&#8201;=&#8201;0.001, diabetic control <italic>p</italic>&#8201;=&#8201;0.001, healthy control <italic>p</italic>&#8201;&lt;&#8201;0.0001</p>
###xml 476 1128 464 1116 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="41"><bold>a</bold> Comparison between the number (<italic>n</italic>) of TRAcP-positive cells formed in cultures with M-CSF and sRANKL (black bars) or with M-CSF, sRANKL and excess concentrations of OPG (250&#160;ng/ml) (grey bars) in patients with Charcot&#8217;s osteoarthropathy and diabetic and healthy control participants. <bold>b</bold> Comparison between the percentage area resorption in the same cultures and patient groups. Statistical differences between the groups were determined using the Mann&#8211;Whitney <italic>U</italic> test, with significance as follows: <bold>a</bold> Charcot&#8217;s <italic>p</italic>&#8201;=&#8201;0.189, diabetic control <italic>p</italic>&#8201;=&#8201;0.005, healthy control <italic>p</italic>&#8201;=&#8201;0.003; <bold>b</bold> Charcot's <italic>p</italic>&#8201;=&#8201;0.001, diabetic control <italic>p</italic>&#8201;=&#8201;0.001, healthy control <italic>p</italic>&#8201;&lt;&#8201;0.0001</p></caption>
###xml 1128 1128 1116 1116 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="125_2008_992_Fig3_HTML" id="MO3"/>
###xml 470 1128 458 1116 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="41"><bold>a</bold> Comparison between the number (<italic>n</italic>) of TRAcP-positive cells formed in cultures with M-CSF and sRANKL (black bars) or with M-CSF, sRANKL and excess concentrations of OPG (250&#160;ng/ml) (grey bars) in patients with Charcot&#8217;s osteoarthropathy and diabetic and healthy control participants. <bold>b</bold> Comparison between the percentage area resorption in the same cultures and patient groups. Statistical differences between the groups were determined using the Mann&#8211;Whitney <italic>U</italic> test, with significance as follows: <bold>a</bold> Charcot&#8217;s <italic>p</italic>&#8201;=&#8201;0.189, diabetic control <italic>p</italic>&#8201;=&#8201;0.005, healthy control <italic>p</italic>&#8201;=&#8201;0.003; <bold>b</bold> Charcot's <italic>p</italic>&#8201;=&#8201;0.001, diabetic control <italic>p</italic>&#8201;=&#8201;0.001, healthy control <italic>p</italic>&#8201;&lt;&#8201;0.0001</p></caption><graphic position="anchor" xlink:href="125_2008_992_Fig3_HTML" id="MO3"/></fig>
###xml 121 129 <span type="species:ncbi:9606">patients</span>
###xml 406 418 <span type="species:ncbi:9606">participants</span>
###xml 672 680 <span type="species:ncbi:9606">patients</span>
###xml 746 758 <span type="species:ncbi:9606">participants</span>
###xml 837 844 <span type="species:ncbi:9606">patient</span>
When OPG was added to the cultures with M-CSF and sRANKL, the reduction in the number of TRAcP-positive cells in Charcot patients was not significant (96.0 +/- 21.6 versus 54.4 +/- 17.6, p = 0.189). OPG on the other hand significantly inhibited the number of TRAcP-positive cells in M-CSF and RANKL-mediated cultures from diabetic (reduced from 56.5 +/- 11.5 to 8.8 +/- 5.3, p = 0.005) and healthy control participants (29.0 +/- 5.1 to 4.4 +/- 1.2, p = 0.003; Fig. 3a). Fig. 3a Comparison between the number (n) of TRAcP-positive cells formed in cultures with M-CSF and sRANKL (black bars) or with M-CSF, sRANKL and excess concentrations of OPG (250 ng/ml) (grey bars) in patients with Charcot's osteoarthropathy and diabetic and healthy control participants. b Comparison between the percentage area resorption in the same cultures and patient groups. Statistical differences between the groups were determined using the Mann-Whitney U test, with significance as follows: a Charcot's p = 0.189, diabetic control p = 0.005, healthy control p = 0.003; b Charcot's p = 0.001, diabetic control p = 0.001, healthy control p < 0.0001
###end p 40
###begin p 41
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 33 34 33 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 284 285 284 285 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 459 460 459 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 497 498 497 498 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 509 510 509 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 537 538 537 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 564 565 564 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 575 576 575 576 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 587 588 587 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 615 616 615 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 642 643 642 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 196 204 <span type="species:ncbi:9606">patients</span>
###xml 270 282 <span type="species:ncbi:9606">participants</span>
###xml 361 368 <span type="species:ncbi:9606">patient</span>
a Comparison between the number (n) of TRAcP-positive cells formed in cultures with M-CSF and sRANKL (black bars) or with M-CSF, sRANKL and excess concentrations of OPG (250 ng/ml) (grey bars) in patients with Charcot's osteoarthropathy and diabetic and healthy control participants. b Comparison between the percentage area resorption in the same cultures and patient groups. Statistical differences between the groups were determined using the Mann-Whitney U test, with significance as follows: a Charcot's p = 0.189, diabetic control p = 0.005, healthy control p = 0.003; b Charcot's p = 0.001, diabetic control p = 0.001, healthy control p < 0.0001
###end p 41
###begin p 42
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Osteoclast resorption</bold>
###xml 177 178 173 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 244 245 236 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 314 315 302 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 345 346 333 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 131 139 <span type="species:ncbi:9606">patients</span>
###xml 326 338 <span type="species:ncbi:9606">participants</span>
Osteoclast resorption The addition of OPG led to a marked reduction of the percentage area resorption on dentine slices in Charcot patients (from 41.6 +/- 8.1% to 5.9 +/- 2.4%, p = 0.001) and also in diabetic (14.2 +/- 16.5% to 0.45 +/- 0.31%, p = 0.001) and healthy control (from 10.5 +/- 1.9% to 0.00 +/- 0.00%, p < 0.0001) participants (Fig. 3b).
###end p 42
###begin p 43
###xml 289 290 283 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 388 389 382 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 420 421 414 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 131 139 <span type="species:ncbi:9606">patients</span>
###xml 275 287 <span type="species:ncbi:9606">participants</span>
###xml 361 369 <span type="species:ncbi:9606">patients</span>
However, the percentage area resorption on the dentine slices was still greater in the cultures with M-CSF, RANKL and OPG from the patients with acute Charcot's osteoarthropathy (5.9 +/- 2.4%) than in those from diabetic (0.45 +/- 0.31%) and healthy control (0.00 +/- 0.00%) participants (p = 0.003). Resorption on the dentine slices was greater in the Charcot patients than in diabetic (p = 0.005) and healthy control (p = 0.003) groups.
###end p 43
###begin title 44
Discussion
###end title 44
###begin p 45
###xml 37 45 <span type="species:ncbi:9606">patients</span>
###xml 259 271 <span type="species:ncbi:9606">participants</span>
###xml 446 454 <span type="species:ncbi:9606">patients</span>
###xml 675 683 <span type="species:ncbi:9606">patients</span>
This study shows that monocytes from patients with acute Charcot's osteoarthropathy cultured in the presence of M-CSF alone were capable of differentiating into mature osteoclasts that exhibited increased resorption compared with diabetic and healthy control participants. Furthermore, osteoclasts generated after the addition of sRANKL were functionally more aggressive, exhibiting a considerable increase in the extent of resorbing activity in patients with acute Charcot's osteoarthropathy. This resorption was partially blocked by the addition of excess concentrations of OPG, a soluble receptor decoy for RANKL. This suggests that the increased osteoclastic activity in patients with acute Charcot's osteoarthropathy is mediated through both a RANKL-dependent and a RANKL-independent pathway.
###end p 45
###begin p 46
###xml 266 267 266 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 611 613 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 615 617 611 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 626 628 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 637 639 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 846 848 842 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 18 26 <span type="species:ncbi:9606">patients</span>
###xml 1036 1048 <span type="species:ncbi:9606">participants</span>
Cultures from the patients with Charcot's osteoarthropathy showed increased osteoclast formation and resorption when cultured with M-CSF alone. Although M-CSF is an essential factor for proliferation, differentiation and survival of the monocyte-macrophage lineage [9, 10], it is not an osteoclastogenic factor and it is unusual to detect osteoclast formation and resorption in cultures with M-CSF, as was seen in the diabetic and healthy controls. This observation suggests that in acute Charcot's osteoarthropathy there may be increased levels of other circulating pro-inflammatory factors such as TNF-alpha [11, 12], IL-6 [13], IL-8 [14] and LIGHT (homologous to lymphotoxins exhibiting inducible expression and competing with herpes simplex virus glycoprotein D for herpes virus entry mediator [HVEM], a receptor expressed by T lymphocytes) [15], which have been previously shown to stimulate osteoclastogenesis independently of RANK/RANKL mechanisms. The concentrations of these circulating factors in diabetic and healthy control participants may not be sufficient to induce the formation and differentiation of active osteoclasts in the presence of M-CSF alone.
###end p 46
###begin p 47
###xml 671 673 671 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
###xml 241 249 <span type="species:ncbi:9606">patients</span>
###xml 736 744 <span type="species:ncbi:9606">patients</span>
###xml 912 920 <span type="species:ncbi:9606">patients</span>
After the addition of sRANKL to M-CSF cultures, the newly formed osteoclasts exhibited markedly increased resorption in the patients with Charcot's osteoarthropathy, although the number of osteoclasts did not significantly increase in these patients compared with cultures with M-CSF alone. These observations may not be unique to Charcot's osteoarthropathy, and indeed similar observations have been reported in other conditions associated with increased bone resorption, such as rheumatoid arthritis where the addition of sRANKL resulted in a significant increase in lacunar resorption, but did not lead to a significant increase in the number of TRAcP-positive cells [16]. Overall, the observed extensive resorption in acute Charcot patients, in the presence of M-CSF and sRANKL, as compared with the diabetic or healthy control groups, may suggest that the osteoclast precursors circulating in acute Charcot patients are in a higher activated state and as such are more primed to becoming osteoclasts (mediated through RANKL) than those in the control groups.
###end p 47
###begin p 48
###xml 479 481 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 1237 1239 1233 1235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 1241 1243 1237 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 1252 1254 1248 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 1263 1265 1259 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 1278 1280 1274 1276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 71 79 <span type="species:ncbi:9606">patients</span>
###xml 810 818 <span type="species:ncbi:9606">patients</span>
In order to ascertain that RANKL was a major osteoclastic activator in patients with Charcot's osteoarthropathy, excess concentrations of OPG, the soluble receptor decoy to RANKL, were added to the cultures with M-CSF and RANKL. The rationale for this approach was that if osteoclastogenesis is mediated solely through RANK-RANKL interaction, addition of excess concentrations of OPG (as had been previously determined to be sufficient to block osteoclastogenesis through RANKL [15]) would completely abolish the process of osteoclast differentiation and activation. In the current study, although osteoclast formation and resorption in the diabetic and healthy control groups was completely blocked by the addition of OPG, the latter did not achieve total inhibition of osteoclast formation and resorption in patients with acute Charcot's osteoarthropathy. These results suggest that although RANKL-dependent pathways do play a significant role in the osteoclastic activity of Charcot's osteoarthropathy, an alternative pathway (other than RANK/RANKL) may also be involved. Osteoclastogenic mediators other than RANKL that have been reported to stimulate osteoclast differentiation independently of the RANKL pathway include TNF-alpha [11, 12], IL-6 [13], IL-8 [14] and LIGHT [15]. In acute Charcot's osteoarthropathy, it is possible that one or a combination of these factors may have initiated the circulating osteoclast precursors to be in a more 'primed' condition, a situation which as such could explain the observed resorption in Charcot monocyte cultures supplemented with M-CSF alone, without the exogenous addition of any osteoclastogenic mediators.
###end p 48
###begin p 49
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 492 494 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 580 581 580 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 844 845 844 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 1147 1149 1147 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 1408 1410 1404 1406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 1542 1544 1538 1540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 1569 1571 1565 1567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 121 129 <span type="species:ncbi:9606">patients</span>
###xml 597 605 <span type="species:ncbi:9606">patients</span>
###xml 1267 1275 <span type="species:ncbi:9606">patients</span>
The osteolysis of Charcot's osteoarthropathy may be explained by our observation that osteoclast precursors from Charcot patients develop into mature osteoclasts that exhibit increased resorptive activity, especially in response to RANKL, unlike the increased resorption in response to bacterial infection, which is not mediated by RANKL [17]. Increased expression of RANKL has been previously demonstrated in pathological osteolysis associated with the development of various bone diseases [18] and a similar mechanism may contribute to osteolysis of Charcot's osteoarthropathy [5]. Furthermore, patients with Charcot's osteoarthropathy have severe neuropathy, which itself can also lead to increased expression of RANKL as a result of the loss of nerve-derived peptides known to antagonise its effect such as calcitonin gene-related peptide [5]. In addition to the RANKL-dependent pathway, our results suggest that a RANKL-independent pathway, mediated by pro-inflammatory cytokines, may also be important. Indeed, Charcot's foot is characterised by excessive inflammation and proinflammatory cytokines have been implicated in its pathogenesis [19]. In support of this, a recent immunohistochemical analysis of bone samples isolated from Charcot's osteoarthropathy patients showed excessive osteoclastic activity in a microenvironment enriched with mediators of bone resorption (IL-1, IL-6 and TNF-alpha) [20]. Thus a RANKL-independent pathway, which is also known to play a role in other osteolytic disorders such as rheumatoid arthritis [21] and aseptic loosening [22], could contribute also to the pathogenesis of the Charcot's osteoarthropathy.
###end p 49
###begin p 50
###xml 684 689 <span type="species:ncbi:9606">human</span>
###xml 782 789 <span type="species:ncbi:9606">patient</span>
###xml 882 889 <span type="species:ncbi:9606">patient</span>
This study has indicated, for the first time that the RANKL-dependent pathway is important in the pathogenesis of Charcot's osteoarthropathy, thereby raising the possibility of the use of RANKL inhibition in the management of Charcot's foot. However, our observations also suggest that a RANKL-independent pathway may play a role, but further investigation is required to fully clarify the mechanism involved. If confirmed, specific pharmacological agents that counteract the RANKL-independent pathway, such as anti-TNF strategies, may be useful in the treatment of Charcot's osteoarthropathy. Whatever the relative importance of either pathway, this in vitro technique of generating human osteoclasts from PBMCs may allow specific characterisation of osteoclastic activity in each patient and could, in the future, lead to individually tailored anti-osteoclastic treatment for the patient with acute Charcot's osteoarthropathy.
###end p 50
###begin title 51
Acknowledgements
###end title 51
###begin p 52
G. Mabilleau was supported by Furlong Charitable Trust. N. L. Petrova was supported by Diabetes UK Grant: BDA:05/0003025 and an EFSD/AstraZeneca Clinical Travel Fellowship.
###end p 52
###begin p 53
###xml 0 19 0 19 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Duality of interest</bold>
Duality of interest The authors declare that there is no duality of interest associated with this manuscript.
###end p 53
###begin title 54
References
###end title 54
###begin article-title 55
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Measurement of markers of osteoclast and osteoblast activity in patients with acute and chronic diabetic Charcot neuroarthropathy
###end article-title 55
###begin article-title 56
Bone resoption by osteoclasts
###end article-title 56
###begin article-title 57
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
###end article-title 57
###begin article-title 58
Clinical implications of the osteoprotegerin/ RANKL /RANK system for bone and vascular diseases
###end article-title 58
###begin article-title 59
Vascular calcification and osteolysis in diabetic neuropathy-is RANK-L the missing link?
###end article-title 59
###begin article-title 60
###xml 11 16 <span type="species:ncbi:9606">human</span>
Generating human osteoclasts from peripheral blood
###end article-title 60
###begin article-title 61
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human osteoclast precursors circulate in the monocyte fraction
###end article-title 61
###begin article-title 62
Charcot neuroarthropathy of the foot
###end article-title 62
###begin article-title 63
Update on the biologic effects of monocyte-macrophage colony-stimulating factor
###end article-title 63
###begin article-title 64
Biological activities and clinical application of M-CSF
###end article-title 64
###begin article-title 65
Tumor necrosis factor alpha stimulates osteoclast differentiation by mechanism independent of ODF/RANKL-RANK-interaction
###end article-title 65
###begin article-title 66
###xml 59 64 <span type="species:ncbi:9606">human</span>
Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation
###end article-title 66
###begin article-title 67
###xml 41 46 <span type="species:ncbi:9606">human</span>
Interleukin-6 and interleukin-11 support human osteoclast formation by RANKL-independent mechanism
###end article-title 67
###begin article-title 68
Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease
###end article-title 68
###begin article-title 69
LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis
###end article-title 69
###begin article-title 70
Osteoclast formation and activity in the pathogenesis of osteoporosis in rheumatoid arthritis
###end article-title 70
###begin article-title 71
Dual modulation of osteoclast differentiation by lipopolysaccharide
###end article-title 71
###begin article-title 72
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis
###end article-title 72
###begin article-title 73
The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes
###end article-title 73
###begin article-title 74
Cytokine-induced osteoclastic bone resorption in Charcot arthropathy: an immunohistochemical study
###end article-title 74
###begin article-title 75
Synovial fluid macrophages are capable of osteoclast formation and resorption
###end article-title 75
###begin article-title 76
Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis
###end article-title 76
###begin title 77
Abbreviations
###end title 77
###begin p 78
homologous to lymphotoxins exhibiting inducible expression and competing with herpes simplex virus glycoprotein D for herpes virus entry mediator (HVEM), a receptor expressed by T lymphocytes
###end p 78
###begin p 79
minimum essential medium
###end p 79
###begin p 80
macrophage-colony stimulating factor
###end p 80
###begin p 81
osteoprotegerin
###end p 81
###begin p 82
peripheral blood monocytes
###end p 82
###begin p 83
receptor activator of nuclear factor-kappaB
###end p 83
###begin p 84
receptor activator of nuclear factor-kappaB ligand
###end p 84
###begin p 85
soluble receptor activator of nuclear factor-kappaB ligand
###end p 85
###begin p 86
tartrate-resistant acid phosphatase
###end p 86

